Hagens Berman is investigating Embecta Corp. for alleged violations of federal securities laws following a pending class action lawsuit. The lawsuit, filed in the U.S. District Court for the District of New Jersey, claims Embecta misrepresented the stability of its insulin pen needle business during the class period from November 25, 2025 to May 4, 2026. On May 5, 2026, Embecta reported a massive revenue decline and slashed its full-year 2026 adjusted EPS guidance by approximately 43% at the midpoint, while also cutting its quarterly dividend by 93% from $0.15 to $0.01 per share. The stock price fell 57.8% in a single trading day following the announcement. The firm is encouraging investors who suffered substantial losses to contact them before the August 17, 2026 lead plaintiff deadline.
Embecta CorpInvestigation and class action lawsuit for alleged securities law violations, plus massive revenue decline and guidance cut.